Effect of MetS* on Cognitive Performance and Physical Activity (Metabolic Syndrome)

NCT05702437 | Unknown

• 1 other identifier: 3274238910
• Study Type: observational
• Target: 82
• Locations: 1 country
• Sites: 1

Brief Summary

Metabolic syndrome (MetS) increases the risk of developing diabetes and cardiovascular disease risk factors that are linked with each other, which is a metabolic dysfunction, which contains a combination of multiple. It is known that METS plays a role in the development of many diseases such as cardiovascular diseases, stroke, cancer, Alzheimer's. Studies have revealed that neuroinflammation, oxidative stress, abnormal lipid metabolism and impaired vascularization, which play a role in the pathogenesis of MetS, affect the structure of the brain and cognition. Atherosclerosis of the carotid artery, increased brain atrophy and white matter damage are potential explanatory mechanisms that lead to an impact on cognitive skills in patients with MetS. In addition, the existence of MetS components such as obesity, diabetes, hypertension alone also negatively affects cognitive functions, and the level of cognitive influence also increases as the number of components an individual has increases. The literature reports that learning, executive functions, processing speed, attention/working memory and global cognitive functions are affected in individuals with MetS, but no consensus has been reached on this issue. Some studies say that MetS causes a significant decrease in cognitive functions, while some studies indicate that this difference is not significant. The aim of our study is to proof the relationship between MetS and cognitive functions with metabolic syndrome components. H1:There is a relationship between the MetS and cognitive functions.

Conditions

Metabolic Syndrome

Keywords

Cognitive Function; Physical Performance; Adults; Chronic Disease

Outcome Measures

Primary Outcomes (8)

• Evaluation of Metabolic Syndrome-waist circumference

  Waist Circumference measurement will be recorded with a tape measure in the middle between the last palpable rib and the upper edge of the iliac crest.

  once, at baseline

• Evaluation of Metabolic Syndrome-blood pressure

  "Omron" digital blood pressure monitor will be used to measure systolic and diastolic blood pressure. Participants will be asked to rest for 5 minutes before the measurement.

  once, at baseline

• Evaluation of Metabolic Syndrome-triglyceride

  Triglyceride, HDL-C and fasting plasma levels and biochemistry laboratory findings of individuals will be evaluated. Before the analysis, 8-12 hours of fasting is required so that it does not affect the test results.

  once, at baseline

• Evaluation of Metabolic Syndrome-HDL-C

  Triglyceride, HDL-C and fasting plasma levels and biochemistry laboratory findings of individuals will be evaluated. Before the analysis, 8-12 hours of fasting is required so that it does not affect the test results.

  once, at baseline

• Evaluation of Metabolic Syndrome-fasting plasma level

  Triglyceride, HDL-C and fasting plasma levels and biochemistry laboratory findings of individuals will be evaluated. Before the analysis, 8-12 hours of fasting is required so that it does not affect the test results.

  once, at baseline

• Metabolic Syndrome Severity Score

  This scoring creates a z-score by considering factors such as age, race, gender, and metabolic syndrome components values. There is a website that automatically calculates the z-score when these data are entered. (https://metscalc.org/metscalc/)

  once, at baseline

• Monreal Cognitive Assessment

  This scale consists of parts that evaluate executive functions, attention and concentration, memory, language, abstract thinking, visual-spatial skills, orientation and calculation. The application of MoCA takes about 10 minutes and the total score of the scale is calculated over 30 points. The threshold point value is 21. Scores of 20 or less are considered cognitive dysfunction.

  once, at baseline

• Stroop Test TBAG Form

  a neuropsychological test that measures focused attention and the speed of information processing

  once, at baseline

Secondary Outcomes (4)

• Mini Mental State Examination

  once, at baseline

• Visual Reaction Test

  once, at baseline

• International Physical Activity Questionnare Short-Form

  once, at baseline

• pedometer

  once, at baseline

Study Arms (2)

MetS Group

it consists of volunteer participants diagnosed with MetS between the ages of 18 and 50. All assessments will be applied to the participants by two different researchers at the same time.

Other: assessment of cognitive performance

Control Group

it will consist of healthy individuals aged 18-50 who do not have any health problems and have volunteered to participate in the study who have undergone a health check within the last 6 months.

Other: assessment of cognitive performance

Interventions

assessment of cognitive performance OTHER

evaluation of the cognitive and physical performance of the participants by two separate researchers at the same time

Also known as: assessment of physical performance

Control Group; MetS Group

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Men and women who have been diagnosed with MetS according to NCEP-ATP III criteria and healthy individuals who do not have any health problems

You may qualify if:

• being between the ages of 18-50
• Having been educated for at least 5 years and know how to read and write
• Having been diagnosed with MetS by meeting 3 of the NCEP-ATP III criteria (for participants in the MetS Group)
• To have a biochemistry test performed within the last 6 months (for the Healthy Group)
• Not having any MetS components (For the Healthy Group)

You may not qualify if:

• Having any neurological, psychiatric and psychological diseases that may affect cognitive status
• Taking antipsychiatric medication
• The presence of any visual-auditory intellectual disability
• Having undergone bariatric surgery

Sponsors & Collaborators

• Istanbul University - Cerrahpasa: lead

Study Sites (1)

Bezmialem Vakif University

Istanbul, 34093, Turkey (Türkiye)

RECRUITING

Related Publications (5)

• Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022 Jan 12;23(2):786. doi: 10.3390/ijms23020786.

  PMID: 35054972 BACKGROUND

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486. No abstract available.

  PMID: 11368702 BACKGROUND

• Bahchevanov KM, Dzhambov AM, Chompalov KA, Massaldjieva RI, Atanassova PA, Mitkov MD. Contribution of Components of Metabolic Syndrome to Cognitive Performance in Middle-Aged Adults. Arch Clin Neuropsychol. 2021 May 21;36(4):498-506. doi: 10.1093/arclin/acaa081.

  PMID: 33067992 BACKGROUND

• Tahmi M, Palta P, Luchsinger JA. Metabolic Syndrome and Cognitive Function. Curr Cardiol Rep. 2021 Oct 19;23(12):180. doi: 10.1007/s11886-021-01615-y.

  PMID: 34668083 BACKGROUND

• Wichayanrat W, Boripuntakul S, Keawtep P, Worakul P, Sungkarat S. Obesity and Brain Health: The Impact of Metabolic Syndrome and Cardiorespiratory Fitness on Cognitive Performances in Middle-Aged Obese Women. J Prev Alzheimers Dis. 2022;9(4):701-707. doi: 10.14283/jpad.2022.54.

  PMID: 36281674 BACKGROUND

MeSH Terms

Conditions

Metabolic Syndrome; Chronic Disease

Condition Hierarchy (Ancestors)

Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Ayca Arslanturk, BSc

  Bezmialem Vakif University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Aysenur Erekdag, MSc

CONTACT

+905548959013; aysenurerekdag@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Investigator

Study Record Dates

• First Submitted: January 15, 2023
• First Posted: January 27, 2023
• Study Start: February 20, 2023
• Primary Completion: December 1, 2024
• Study Completion: May 1, 2025
• Last Updated: January 12, 2024

Record last verified: 2024-01

Locations

TU (1)